SCHEMBL1347432

SCHEMBL1347432

NC(=O)c1ccc(F)c(-c2ccc(C=O)cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.43
ERN1 O75460 2/20 0.40
PARP10 Q53GL7 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
AR P10275 4/20 0.40
BRD4 O60885 1/20 0.38
VNN1 O95497 2/20 0.38
KDM1A O60341 1/20 0.37
CCNE2 O96020 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
HDAC1 Q13547 1/20 0.34
PARP1 P09874 1/20 0.34
NNMT P40261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346048 0.76 KDM1A (0.56) HPGDSERN1KDM1ACDK2
SCHEMBL1347688 0.74 OPRM1 (0.53) HDAC1ALDH1A1
SCHEMBL913181 0.73 NPC1 (0.49) ALDH1A1L3MBTL1
SCHEMBL12607546 0.73 ERN1 (0.55) ERN1PARP10PARP3ARALDH1A1
SCHEMBL9607471 0.71 ALDH1A1 (0.45) HDAC1ALDH1A1L3MBTL1
SCHEMBL28040903 0.70 FEN1 (0.54) HPGDSCCNE2CCNE1CDK2ALDH1A1
SCHEMBL31152601 0.69 KDM1A (0.48) KDM1AHDAC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL22756714 0.69 GRM5 (0.42) ALDH1A1
SCHEMBL13475339 0.68 P4HA1 (0.71) SMN1; SMN2ALDH1A1
SCHEMBL1356310 0.68 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
EP-2197835-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS Prosidion Limited (GB) 2010-06-23 EP disclosed
WO-2009030962-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2009-03-12 WO disclosed
WO-2009030962-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 HPGDS 1816/4885ERN1 3519/4885PARP10 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.